- Home
- SNGX vs IMRN Comparison
SNGX vs IMRN Comparison
Compare SNGX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- IMRN
- Stock Information
- Founded
- SNGX 1987
- IMRN 1994
- Country
- SNGX United States
- IMRN Australia
- Employees
- SNGX N/A
- IMRN N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- IMRN Health Care
- Exchange
- SNGX Nasdaq
- IMRN Nasdaq
- Market Cap
- SNGX 10.1M
- IMRN 9.2M
- IPO Year
- SNGX 1987
- IMRN N/A
- Fundamental
- Price
- SNGX $2.86
- IMRN $1.86
- Analyst Decision
- SNGX Strong Buy
- IMRN Strong Buy
- Analyst Count
- SNGX 1
- IMRN 1
- Target Price
- SNGX $6.00
- IMRN $5.00
- AVG Volume (30 Days)
- SNGX 10.2M
- IMRN 55.1K
- Earning Date
- SNGX 11-07-2025
- IMRN 08-29-2025
- Dividend Yield
- SNGX N/A
- IMRN N/A
- EPS Growth
- SNGX N/A
- IMRN N/A
- EPS
- SNGX N/A
- IMRN N/A
- Revenue
- SNGX N/A
- IMRN $4,777,422.00
- Revenue This Year
- SNGX N/A
- IMRN N/A
- Revenue Next Year
- SNGX N/A
- IMRN N/A
- P/E Ratio
- SNGX N/A
- IMRN N/A
- Revenue Growth
- SNGX N/A
- IMRN 48.63
- 52 Week Low
- SNGX $1.09
- IMRN $1.50
- 52 Week High
- SNGX $6.23
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- SNGX 49.77
- IMRN 56.87
- Support Level
- SNGX $2.72
- IMRN $1.73
- Resistance Level
- SNGX $3.11
- IMRN $1.89
- Average True Range (ATR)
- SNGX 0.49
- IMRN 0.10
- MACD
- SNGX -0.10
- IMRN 0.01
- Stochastic Oscillator
- SNGX 3.99
- IMRN 76.77
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.